CU20200048A7 - Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina - Google Patents

Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina

Info

Publication number
CU20200048A7
CU20200048A7 CU2020000048A CU20200048A CU20200048A7 CU 20200048 A7 CU20200048 A7 CU 20200048A7 CU 2020000048 A CU2020000048 A CU 2020000048A CU 20200048 A CU20200048 A CU 20200048A CU 20200048 A7 CU20200048 A7 CU 20200048A7
Authority
CU
Cuba
Prior art keywords
receptor
triazolobenzazepines
vasopressin
antagonists
refers
Prior art date
Application number
CU2020000048A
Other languages
English (en)
Other versions
CU24630B1 (es
Inventor
Ferenc Baska
Imre Bata
Éva Bozó
Kordás Krisztina Szondiné
Krisztina Vukics
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CU20200048A7 publication Critical patent/CU20200048A7/es
Publication of CU24630B1 publication Critical patent/CU24630B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La presente invención se refiere a un de fórmula general (I) útiles en el tratamiento y/o profilaxis de una enfermedad o afección asociada con la función del receptor V1a. Se refiere también a la composición farmacéutica y a una composición combinatoria que comprende este compuesto junto con uno o más principios activos adicionales.</p> <p>(ESPACIO PARA LA FORMULA)</p>
CU2020000048A 2017-12-15 2018-12-14 Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina CU24630B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1700521A HU231206B1 (hu) 2017-12-15 2017-12-15 Triazolobenzazepinek
PCT/IB2018/060077 WO2019116324A1 (en) 2017-12-15 2018-12-14 Triazolobenzazepines as vasopressin v1a receptor antagonists

Publications (2)

Publication Number Publication Date
CU20200048A7 true CU20200048A7 (es) 2021-03-11
CU24630B1 CU24630B1 (es) 2022-12-12

Family

ID=89992589

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000048A CU24630B1 (es) 2017-12-15 2018-12-14 Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina

Country Status (23)

Country Link
US (1) US11298363B2 (es)
EP (1) EP3724192B1 (es)
JP (1) JP7428647B2 (es)
KR (1) KR102719165B1 (es)
CN (1) CN111479813B (es)
AR (1) AR113933A1 (es)
AU (1) AU2018385724B2 (es)
BR (1) BR112020011880A2 (es)
CA (1) CA3085562A1 (es)
CL (1) CL2020001564A1 (es)
CU (1) CU24630B1 (es)
EA (1) EA202091344A1 (es)
HU (1) HU231206B1 (es)
IL (1) IL275084B2 (es)
JO (1) JOP20200149B1 (es)
MX (1) MX2020006204A (es)
PE (1) PE20210671A1 (es)
PH (1) PH12020500548A1 (es)
SG (1) SG11202005299VA (es)
TN (1) TN2020000083A1 (es)
TW (1) TWI826406B (es)
UA (1) UA129516C2 (es)
WO (1) WO2019116324A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
WO2022018121A1 (en) * 2020-07-23 2022-01-27 F. Hoffmann-La Roche Ag Cyclohexyl substituted triazoles as vasopressin receptor v1 a antagonists
WO2022135335A1 (zh) * 2020-12-21 2022-06-30 上海济煜医药科技有限公司 三氮唑类三并环衍生物及其制备方法和应用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females
US12310974B1 (en) 2023-12-19 2025-05-27 Samuel Aballea Method of treating post-traumatic stress disorder with carpipramine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382185B1 (en) 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
DE69434032T2 (de) 1993-07-21 2005-09-22 Yamanouchi Pharmaceutical Co., Ltd. Zwischenprodukt zur Herstellung von kondensierten Benzazepinderivate
DK0765314T3 (da) 1994-06-15 2003-08-25 Otsuka Pharma Co Ltd Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
JP3873746B2 (ja) 2000-05-19 2007-01-24 アステラス製薬株式会社 トリアゾール誘導体
MXPA03000135A (es) 2000-07-05 2005-02-17 Johnson & Johnson Espirobenzoazepinas sustitudas no peptidicas como antagonistas de vasopresina.
CA2425892A1 (en) 2000-11-28 2003-04-11 Hiroyuki Koshio 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof
AU2002342045C1 (en) 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
KR100750028B1 (ko) 2003-02-19 2007-08-16 화이자 인코포레이티드 치료에 유용한 트리아졸 화합물
GB0303852D0 (en) * 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
MX2007002248A (es) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
JP2008526702A (ja) 2004-12-31 2008-07-24 アボット ゲーエムベーハー ウント カンパニー カーゲー 置換オキシインドール誘導体、該誘導体を含んでいる薬物及びそれらの使用
CA2602194A1 (en) 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituted oxindol derivatives, drugs containing said derivatives and the use thereof
RU2007146444A (ru) 2005-05-13 2009-06-20 Лексикон Фармасьютикалз, Инк. (Us) Полициклические соединения и способы их применения
KR100974967B1 (ko) 2005-07-14 2010-08-09 에프. 호프만-라 로슈 아게 Ｖ1ａ 수용체 길항물질로서의인돌-3-카본일-스피로-피페리딘 유도체
CN101268067A (zh) 2005-07-21 2008-09-17 弗·哈夫曼-拉罗切有限公司 作为v1a受体拮抗剂的吲哚-3-基-羰基-哌啶-苯并咪唑衍生物
CN102295636A (zh) 2005-07-29 2011-12-28 弗·哈夫曼-拉罗切有限公司 吲哚-3-基-羰基-哌啶和哌嗪衍生物
DE102006051796A1 (de) * 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
JP2010517966A (ja) 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の処置のための１−オキサ−３−アザスピロ（４．５）デカン−２−オンおよび１−オキサ−３，８−ジアザスピロ（４．５）デカン−２−オン誘導体
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
TW201103907A (en) 2009-03-20 2011-02-01 Lundbeck & Co As H Amide derivatives as neuropeptide Y5 receptor ligands
AU2010312651A1 (en) 2009-10-26 2012-05-03 Otsuka Pharmaceutical Co., Ltd. Benzazepine compound
GB201004677D0 (en) 2010-03-19 2010-05-05 Vantia Ltd New salt
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
JP2013542266A (ja) * 2010-11-15 2013-11-21 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物、および方法
EP2900672B1 (de) * 2012-09-28 2017-02-22 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 5-aryl-triazolo-azepine
JP2016513112A (ja) 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
AU2015359626B2 (en) 2014-12-09 2020-07-23 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
CN106349241B (zh) * 2015-07-15 2020-04-21 上海翰森生物医药科技有限公司 具有hsp90抑制活性的三唑衍生物及其制备方法和应用
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10815205B2 (en) 2016-05-03 2020-10-27 Bayer Pharma Aktiengesellschaft Amide-substituted phenyltriazole derivatives and uses thereof
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
TWI826406B (zh) 2023-12-21
IL275084A (en) 2020-07-30
UA129516C2 (uk) 2025-05-21
JP7428647B2 (ja) 2024-02-06
KR102719165B1 (ko) 2024-10-17
HU231206B1 (hu) 2021-10-28
IL275084B2 (en) 2023-06-01
TN2020000083A1 (en) 2022-01-06
BR112020011880A2 (pt) 2020-11-24
PH12020500548A1 (en) 2021-01-25
CA3085562A1 (en) 2019-06-20
AU2018385724B2 (en) 2023-05-25
EA202091344A1 (ru) 2020-09-09
CL2020001564A1 (es) 2020-11-06
EP3724192B1 (en) 2022-08-03
MX2020006204A (es) 2020-08-27
AR113933A1 (es) 2020-07-01
CU24630B1 (es) 2022-12-12
CN111479813A (zh) 2020-07-31
US20210260072A1 (en) 2021-08-26
AU2018385724A1 (en) 2020-07-09
US11298363B2 (en) 2022-04-12
TW201938170A (zh) 2019-10-01
SG11202005299VA (en) 2020-07-29
JOP20200149B1 (ar) 2022-10-30
HUP1700521A2 (en) 2019-06-28
JP2021506821A (ja) 2021-02-22
PE20210671A1 (es) 2021-04-05
JOP20200149A1 (ar) 2020-06-10
EP3724192A1 (en) 2020-10-21
CN111479813B (zh) 2023-03-21
KR20200100111A (ko) 2020-08-25
WO2019116324A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
CU20200048A7 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina
CL2017001362A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2020001394A1 (es) Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CL2018002671A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2017014880A (es) Composiciones farmaceuticas y uso de las mismas.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
MX2023011761A (es) Moduladores de los receptores opioides.
CL2017002229A1 (es) Inhibidores de bace1.
CU20170134A7 (es) 2-tiopirimidinonas
EA201791456A1 (ru) Пептиды-антагонисты cgrp